GlassScriptPhysician profile
Belinda A Dure-Smith
NPI 1487620662
$2,563.09
in general payments reported to CMS, 2019-2025
36 companies · $496 in 2025
The $496 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,036 · 2020: $163 · 2021: $96.01 · 2022: $248 · 2023: $261 · 2024: $263 · 2025: $496.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,020.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,020.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $431.64 | 2019-2024 | Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $251.12 | 2019-2025 | Airsupra, Farxiga |
| Novo Nordisk INC | $193.22 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $178.89 | 2019-2025 | Mounjaro, Jardiance, Kisunla |
| Pfizer INC. | $165.66 | 2019-2025 | |
| Amgen INC. | $147.21 | 2019-2025 | Repatha, Otezla, Evenity |
| Braemar Manufacturing, LLC | $143.91 | 2019 | |
| Sunovion Pharmaceuticals INC. | $131.01 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $114.72 | 2019-2020 | |
| Astellas Pharma US INC | $98.85 | 2019-2024 | Veozah |
| Hologic Sales and Service, LLC | $69.26 | 2019-2025 | Aptima |
| Allergan, INC. | $62.35 | 2019 | |
| Abbvie INC. | $56.99 | 2023 | Vraylar |
| Boehringer Ingelheim Pharmaceuticals, INC. | $47.04 | 2025 | Jardiance |
| Shield Therapeutics INC | $44.65 | 2025 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $38.33 | 2019 | |
| Radius Health, INC. | $33.34 | 2019 | |
| Amarin Pharma, INC. | $31.06 | 2019-2020 | |
| Acadia Pharmaceuticals INC | $29.36 | 2023 | Nuplazid |
| Irhythm Technologies, INC. | $27.55 | 2022 | |
| Ibsa Pharma INC. | $22.77 | 2025 | Tirosint, Flector, Licart |
| Jazz Pharmaceuticals INC. | $22.44 | 2021 | |
| Si-Bone, INC. | $22.43 | 2024 | |
| Abbott Laboratories | $21.70 | 2022 | |
| Novartis Pharmaceuticals Corporation | $19.30 | 2019 | |
| Sumitomo Pharma America, INC. | $17.47 | 2025 | Gemtesa |
| E.R. Squibb & Sons, L.L.C. | $17.13 | 2019 | |
| Therapeuticsmd, INC. | $16.10 | 2019 | |
| Vertiflex, INC. | $15.95 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.57 | 2023 | Xifaxan |
| Exact Sciences Corporation | $13.74 | 2023 | Cologuard Collection Kit |
| Biohaven Pharmaceutical Holding Company LTD. | $13.30 | 2022 | |
| Cequr Corporation | $12.95 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $12.89 | 2020 | |
| Tactile Systems Technology INC | $12.49 | 2022 | |
| Biowound Solutions, INC. | $10.70 | 2025 | Bio-Connekt |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Belinda Dure-Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.